Voyager Therapeutics no longer expects to sail its amyotrophic lateral sclerosis (ALS) candidate into the clinic in the coming months as the gene therapy company looks to rejig the asset’s payload.

announced today it is reassessing its gene therapy program for a form of amyotrophic lateral sclerosis (ALS) due to unforeseen challenges with its current treatment candidate. According to ...

A new review highlights the pivotal role of LSD1 (lysine-specific demethylase 1) in regulating critical cellular processes ...

Integrative transcriptomics in amyotrophic lateral sclerosis models and patients reveals a conserved type I and type II interferon gene signature driven by STING-mediated innate immune activation.

ALS, which is also known as Lou Gehrig's Disease, is a rare neurological disease that affects motor neurons — the nerve cells ...

Voyager Therapeutics Inc. has announced its decision to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). Emerging ...

Nevertheless, the new disappointment with DNL343 is another major disappointment to ALS patients, who have limited drug ...

Positron emission tomography (PET) is a nuclear imaging technique used to diagnose conditions such as cancer. An innovative ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Free Report) has been assigned an average recommendation of “Buy” from the nine ...